| Literature DB >> 25221655 |
Zhisen Zhang1, Zhaohu Lin1, Zheng Zhou1, Hong C Shen1, S Frank Yan1, Alexander V Mayweg1, Zhiheng Xu1, Ning Qin1, Jason C Wong1, Zhenshan Zhang1, Yiping Rong1, David C Fry2, Taishan Hu1.
Abstract
The YAP-TEAD protein-protein interaction (PPI) mediates the oncogenic function of YAP, and inhibitors of this PPI have potential usage in treatment of YAP-involved cancers. Here we report the design and synthesis of potent cyclic peptide inhibitors of the YAP-TEAD interaction. A truncation study of YAP interface 3 peptide identified YAP(84-100) as a weak peptide inhibitor (IC50 = 37 μM), and an alanine scan revealed a beneficial mutation, D94A. Subsequent replacement of a native cation-π interaction with an optimized disulfide bridge for conformational constraint and synergistic effect between macrocyclization and modification at positions 91 and 93 greatly boosted inhibitory activity. Peptide 17 was identified with an IC50 of 25 nM, and the binding affinity (K d = 15 nM) of this 17mer peptide to TEAD1 proved to be stronger than YAP(50-171) (K d = 40 nM).Entities:
Keywords: Peptide inhibitor; TEAD; YAP; conformational constraint; protein−protein interaction
Year: 2014 PMID: 25221655 PMCID: PMC4160762 DOI: 10.1021/ml500160m
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345